Financial Performance - The company achieved operating revenue of CNY 720.06 million in 2023, an increase of 3.04% compared to CNY 698.83 million in 2022[22]. - The net profit attributable to shareholders was a loss of CNY 10.87 million in 2023, improving from a loss of CNY 78.83 million in 2022[22]. - The net cash flow from operating activities was CNY 215.23 million, a significant recovery from a negative cash flow of CNY -160.09 million in 2022[22]. - The basic earnings per share for 2023 was -CNY 0.0396, an improvement from -CNY 0.2873 in 2022[23]. - The quarterly revenue for Q4 2023 was CNY 158.00 million, with a net profit loss of CNY -11.52 million, indicating fluctuations in performance throughout the year[26]. - Operating costs rose to 111.79 million yuan, reflecting a 12.55% increase year-on-year, resulting in a gross margin of 84.47%, down 1.31 percentage points[81]. - The company reported a net profit attributable to shareholders of -10.87 million yuan, with a net profit excluding non-recurring items of -3.54 million yuan[79]. - The revenue from antiviral drugs reached CNY 64,282.65 million, with a gross margin of 90.23%, reflecting a year-on-year revenue increase of 39.27%[111]. Research and Development - Research and development expenses accounted for 12.94% of operating revenue, up from 9.22% in the previous year, indicating increased investment in innovation[23]. - The company has 22 new products in development, including 7 innovative drug projects and 13 generic drug projects[33]. - The company has filed for 3 new invention patents and received 3 new authorized patents during the reporting period, totaling 35 authorized patents[33]. - The company has increased its R&D investment by 44.57% compared to the previous year, primarily due to increased clinical research costs for the drug Meifurenketone and improvements in the processes for Palivizumab Sodium Injection and Lactic Acid Ciprofloxacin Sodium Injection[57]. - The total R&D expenditure for the year is approximately ¥93.18 million, with a significant increase in capitalized R&D investment by 190.93% to ¥18.32 million[59]. - The company has developed core technologies in drug design and discovery, which are essential for new drug development[50]. - The company is conducting Phase II clinical trials for a new innovative drug targeting diabetic nephropathy, which is expected to be a significant breakthrough in treatment[33]. - The company is conducting Phase II clinical trials for a modified new drug, an inhalation solution of peramivir, which aims to be the world's first nebulized inhalation antiviral drug[45]. Corporate Governance - The company has not disclosed any special arrangements for corporate governance[8]. - The company has established a governance structure that includes a board of directors, supervisory board, and senior management, ensuring checks and balances[137]. - The board consists of 7 members, including 3 independent directors, ensuring a fair and transparent election process[138]. - The company has implemented a comprehensive internal control system to maintain effective oversight of its management team[141]. - The company adheres to strict information disclosure practices, ensuring transparency and equal access to information for all shareholders[141]. - The company held four shareholder meetings during the reporting period, all resolutions were approved without any rejections[146]. - The company has not reported any changes in shareholding for its directors and senior management during the reporting period[148]. - The company has maintained its internal control audit institution for 2023[146]. Market and Sales Strategy - The company is expanding its sales channels and adjusting its sales model to achieve steady revenue growth[34]. - The company has established a marketing network covering over 30 provinces, focusing on expanding the OTC market and enhancing brand awareness[36]. - The company is focusing on optimizing the evaluation and approval process for radioactive drugs, which are crucial for treating serious diseases[49]. - The company is actively planning new product launches to create new revenue and profit growth points[35]. - The company is focusing on expanding its product line in the antiviral and infectious disease treatment sectors, with a strong emphasis on innovative drugs[66]. - The company is accelerating the layout of its product lines in cardiovascular diseases, respiratory diseases, and antipyretic analgesics, with existing products including Benazepril Hydrochlorothiazide tablets and Atorvastatin Calcium tablets[68]. Risk Factors - The company emphasizes the importance of risk factors in its forward-looking statements, urging investors to be cautious[6]. - The company faces risks related to the lengthy and costly new drug approval process, with uncertainty regarding the success of its clinical trials and regulatory approvals for its pipeline products[73]. - The company’s core product, Palivizumab Sodium Injection, is at risk of being replicated by competitors, which could lead to increased market competition and potential price declines[75]. - The company faced risks related to centralized procurement policies that could significantly affect sales revenue and volumes of its main products[77]. Compliance and Regulatory Matters - The company received administrative regulatory measures from the China Securities Regulatory Commission on April 26, 2023, requiring corrections to prior accounting errors[168]. - The company disclosed corrected annual and quarterly reports for 2020 and 2021 on June 28, 2023, confirming the rectification of accounting errors[169]. - The company submitted a rectification report to the Shanghai Stock Exchange on July 5, 2023, in response to a regulatory warning received on June 6, 2023[170]. - The company has been actively addressing regulatory measures from the Hunan Securities Regulatory Bureau as part of its compliance efforts[173]. Employee and Management - The total remuneration for all directors, supervisors, and senior management at the end of the reporting period amounted to 4.8608 million RMB[164]. - The total remuneration for core technical personnel at the end of the reporting period amounted to 2.6229 million RMB[164]. - The company has a competitive compensation policy, providing various insurance and benefits to employees[187]. - The company employed a total of 360 staff, with 50 in the parent company and 310 in major subsidiaries[186]. - A total of 14 external training sessions and 344 internal training sessions were conducted in 2023 to enhance employee skills and teamwork[189].

湖南南新制药股份有限公司（以下简称"公司"）第二届监事会第十三次会 议于 2025 年 4 月 28 日在广州南新制药有限公司 313 会议室以现场与通讯相结合 的方式召开。 本次会议通知于 2025 年 4 月 21 日以邮件方式向全体监事发出，本次会议应 出席监事 3 人，实际出席监事 3 人。本次会议的召集、召开程序均符合《公司法》 《证券法》等法律法规和规范性文件以及《公司章程》的规定。 二、监事会会议审议情况 本次会议由公司监事会主席张平丽女士主持。经与会监事认真审议，以记名 投票方式，通过了如下议案： 证券代码：688189 证券简称：南新制药 公告编号：2025-006 湖南南新制药股份有限公司 第二届监事会第十三次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、监事会会议召开情况 （一）审议通过《关于<2024 年度监事会工作报告>的议案》 2024 年度，公司监事会严格遵守《公司法》《证券法》以及《公司章程》的 有关规定，以维护公司利益、股东权益为原则，勤勉履行法律和股东所赋予的职 责和 ...

Group 1: US Tariff Plans and Market Reactions - President Trump plans to announce new tariffs in the coming days, indicating a willingness to negotiate tariff agreements with other countries, but any agreements will likely occur after the tariffs take effect on April 2 [1] - The US stock market saw significant declines, with the Nasdaq dropping 2.7%, the S&P 500 down 1.97%, and the Dow Jones falling 1.69% [1][4] Group 2: Technology Sector Performance - Major tech stocks experienced declines, with Netflix, Google, Amazon, and Meta falling over 4%, while Tesla, Microsoft, and Intel dropped over 3% [2] - The Nasdaq Golden Dragon China Index fell by 3.11%, with popular Chinese stocks like Baidu and NIO dropping over 5% [2] Group 3: IPO Market Developments - Wolfspeed's stock plummeted approximately 52%, marking the worst single-day performance for an IPO in the US [3] - CoreWeave's IPO closed flat at $40 on its first day of trading [3] Group 4: Commodity Market Trends - COMEX gold futures for June rose by 0.59% to $3116.6, marking a weekly increase of 2.26% [4] - WTI crude oil futures for May fell by 0.8% to $69.36 per barrel, with a weekly increase of 1.58% [4] Group 5: Regulatory and Taxation News - The Trump administration is unexpectedly considering higher taxes on the wealthy, which could provide room for other priority issues [6] - The EU plans to impose mild penalties on Apple and Meta under its digital market regulations, potentially leading to fines amounting to billions of dollars [8] Group 6: Market Movements and Trends - The six major state-owned banks in China reported a total net profit of approximately 1.4 trillion yuan for 2024, averaging about 38 billion yuan per day [17] - The Chinese central bank stated that current financial risks are overall controllable, with the financial system's resilience expected to improve as the macro economy recovers [20]

一、本次交易概述 湖南南新制药股份有限公司（以下简称"公司"）于 2024 年 11 月 15 日召开 了第二届董事会第十三次会议和第二届监事会第十一次会议，2024 年 12 月 2 日 召开 2024 年第一次临时股东大会，审议通过了《关于拟公开挂牌转让全资子公 司 100%股权的议案》和《关于转让全资子公司股权暨被动形成财务资助的议案》， 同意在湖南省联合产权交易所有限公司公开挂牌转让公司的全资子公司常德臻 诚医药科技有限公司 100%股权，具体内容详见公司于 2024 年 11 月 16 日披露的 《关于拟公开挂牌转让全资子公司 100%股权暨被动形成财务资助的公告》（公告 编号：2024-047）。 二、本次交易终止的情况 证券代码：688189 证券简称：南新制药 公告编号：2025-004 特此公告。 湖南南新制药股份有限公司 关于终止挂牌转让全资子公司 100%股权的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 本次交易挂牌期满后，公司对市场情况进行再次调研论证，经审慎研究，公 司决定终止本次挂牌转 ...

Financial Performance - Total revenue for 2024 was CNY 27,398.33 million, a decrease of 63.20% compared to the previous year[4] - Operating profit for 2024 was CNY -39,189.22 million, a decline of 5,387.12% year-over-year[4] - Net profit attributable to shareholders of the parent company was CNY -35,423.77 million, down 9,542.56% from the previous year[4] - Basic earnings per share for 2024 were CNY -1.2910, a decrease of 9,523.36% compared to the previous year[4] - The weighted average return on net assets was -31.18%, a decrease of 31.47 percentage points compared to the previous year[4] Assets and Equity - Total assets at the end of 2024 were CNY 123,373.35 million, a reduction of 29.00% from the previous year[6] - Shareholders' equity attributable to the parent company was CNY 95,387.82 million, down 27.63% year-over-year[6] Strategic Adjustments - The company adjusted sales strategies and reduced prices for core products due to industry policy changes and increased market competition[7] - The company implemented cost reduction measures, resulting in a significant decrease in selling, administrative, and financial expenses compared to the previous year[7] Report Accuracy - There are no significant uncertainties affecting the accuracy of the performance report[9]

Financial Performance Forecast - The company expects a net loss attributable to shareholders of the parent company for 2024 to be between -260 million and -360 million yuan[4]. - The net profit attributable to shareholders of the parent company, excluding non-recurring gains and losses, is projected to be between -262 million and -362 million yuan for 2024[4]. - In 2023, the total profit was 7.6073 million yuan, with a net profit attributable to shareholders of the parent company of 3.7515 million yuan[5]. - The net profit attributable to shareholders of the parent company, excluding non-recurring gains and losses, was 11.0774 million yuan in 2023[5]. Market and Operational Challenges - The company has adjusted and optimized sales strategies due to industry policy environment and intensified market competition, leading to a decrease in sales prices for core products[6]. - The company has experienced a decline in operating income and gross margin due to fewer flu cases in the second, third, and fourth quarters of 2024[6]. Cost Management and Strategic Adjustments - The company has implemented cost reduction and efficiency improvement measures, resulting in a significant decrease in selling, administrative, and financial expenses compared to the previous year[7]. - The company plans to further adjust marketing strategies and enhance cost control to strengthen core competitiveness and respond to industry changes[7]. Earnings Forecast Reliability - There are no significant uncertainties affecting the accuracy of this earnings forecast[8]. - The preliminary financial data may differ from the final figures disclosed in the 2024 annual report[9].

北京大成（广州）律师事务所 关于湖南南新制药股份有限公司 2024 年第二次临时股东大会的 法律意见书 guangzhou.dachenglaw.com 广州市天河区珠江新城珠江东路 6 号广州周大福金融中心 14 层、15 层（510623） 14/F,15/F CTF Finance Centre No 6 Zhujiang East Road Tianhe District 510623, Guangzhou, China Tel:+8620-85277000 Fax:+8620-85277002 关于湖南南新制药股份有限公司 2024 年第二次临时股东大会的法律意见书 致：湖南南新制药股份有限公司 根据《中华人民共和国证券法》（以下简称"《证券法》"）、《中华人民共 和国公司法》（以下简称"《公司法》"）和中国证券监督管理委员会《上市公司 股东大会规则（2022 年修订）》（以下简称"《股东大会规则》"）等法律、法规 和其他有关规范性文件的要求，北京大成（广州）律师事务所（以下简称"本所"） 接受湖南南新制药股份有限公司（以下简称"公司"）的委托，指派律师参加公司 2024 年第二次临时股东大会（以下 ...

证券代码：688189 证券简称：南新制药 公告编号：2024-058 湖南南新制药股份有限公司 2024 年第二次临时股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东大会召开的时间：2024 年 12 月 27 日 （二） 股东大会召开的地点：广东省广州市黄埔区开源大道 196 号广州南新制 药有限公司 313 会议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： 本次股东大会由湖南南新制药股份有限公司（以下简称"公司"）董事会召 集，由董事长胡新保先生主持，会议采用现场投票与网络投票相结合的表决方式 进行表决。本次会议的召集、召开程序与表决方法、表决程序符合《公司法》《公 司章程》及《上海证券交易所科创板股票上市规则》等法律、法规和规范性文件 的规定。 （五） 公司董事、监事和董事会秘书的出席情况 1、 公司在任董事 7 人，出席 7 人； 2、 公司在任监事 3 人， ...

帕拉米韦吸入溶液是公司自主研发的国家 2.2 类改良型新药，是对公司现有 1.1 类新药帕拉米韦氯化钠注射液的剂型创新。公司积极开发帕拉米韦吸入溶液， 本品可扩大临床应用场景，提高患者用药的依从性和便捷性，惠及更多人群，对 临床流感防治具有重要意义。 证券代码：688189 证券简称：南新制药 公告编号：2024-057 帕拉米韦吸入溶液已完成Ⅱ期临床试验（登记号：CTR20233494），试验结果 表明：在有效性方面，对中国无并发症的成人单纯性流感患者给予帕拉米韦吸入 溶液，能够有效缩短流感病毒转阴时间、有效缩短流感症状的持续时间；在安全 性方面，帕拉米韦吸入溶液各组不良事件（AE）均以 1 级为主，均未发生严重程 度为 3 级及以上的不良事件，其安全性良好。 湖南南新制药股份有限公司 基于前期临床试验获得良好的有效性和安全性，本项目获得许可开展Ⅲ期确 证性临床试验"评价帕拉米韦吸入溶液治疗成人无并发症单纯性流感的有效性及 安全性的多中心、随机、双盲、安慰剂平行对照的Ⅲ期临床研究"，组长单位为 中国人民解放军总医院。公司将严格按照药物监管部门要求，遵循药物临床试验 质量管理规范，快速推进Ⅲ期临床试验工作。 ...

西部证券股份有限公司 关于湖南南新制药股份有限公司 使用部分闲置募集资金暂时补充流动资金的核查意见 西部证券股份有限公司（以下简称"西部证券"或"保荐人"）作为湖南南新制 药股份有限公司（以下简称"南新制药"或"公司"）首次公开发行股票并在科创 板上市的保荐人，根据《证券发行上市保荐业务管理办法》《上海证券交易所科创板 股票上市规则（2024年4月修订）》《上市公司监管指引第2号——上市公司募集资金 管理和使用的监管要求（2022年修订）》《上海证券交易所科创板上市公司自律监管 指引第1号——规范运作（2023年12月修订）》以及《上海证券交易所上市公司自律 监管指引第11号——持续督导 （2023年8月修订）》等相关规定履行持续督导职责， 对南新制药拟使用闲置募集资金暂时补充流动资金事项进行了核查，核查情况及核 查意见如下： 一、募集资金基本情况 根据中国证券监督管理委员会《关于同意湖南南新制药股份有限公司首次公开发 行股票注册的批复》（证监许可〔2020〕318 号），湖南南新制药股份有限公司首次 向社会公众公开发行人民币普通股（A 股）3,500.00 万股，每股面值人民币 1 元，每 股发行价格为人民 ...